.: OKULISTYKA :.

Wydanie 1/2016
str. 83 - 85

Deksametazon (Ozurdex) w leczeniu obrzęku plamki w przebiegu niedrożności naczyń żylnych siatkówki – retrospektywne badanie przeprowadzone w Polsce

Dexamethasone (Ozurdex) in the Treatment of Macular Oedema Following Retinal Vein Occlusion – Retrospective Study in Poland

Agnieszka Kubicka-Trząska¹, Katarzyna Michalska-Małecka², Andrzej Dmitriew³, Alicja Dębicka⁴, Urszula Gajdzik-Gajdecka⁵, Aneta Adamczyk-Ludyga⁵, Magdalena Ulińska⁶, Dominik Zalewski⁷, Marzena Lipińska⁸, Mateusz Nikodem⁸, Bożena Romanowska-Dixon¹

¹Oddział Kliniczny Kliniki Okulistyki i Onkologii Okulistycznej Szpitala Uniwersyteckiego w Krakowie
Kierownik: prof. dr hab. n. med. Bożena Romanowska-Dixon
²Klinika Okulistyki Katedry Okulistyki, Wydział Lekarski w Katowicach, Śląski Uniwersytet Medyczny w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek
³Katedra i Klinika Okulistyki Uniwersytetu Medycznego w Poznaniu
Kierownik: dr hab. n. med. Jarosław Kocięcki, prof. UM
⁴Centrum Medyczne VISUS w Starachowicach
⁵Oddział Okulistyki Szpitala EuroMedic
⁶Katedra i Klinika Okulistyki II Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego
Kierownik: prof. dr hab. n. med. Jacek P. Szaflik
⁷Centrum Diagnostyki i Mikrochirurgii Oka LENS
⁸ Instytut Arcana Ltd (CRO)

Summary: Purpose: The objective of multi-centre study performed in Poland was to evaluate the efficacy and safety of dexamethasone injection in the treatment of macular oedema due to retinal vein occlusion.
Material and methods: The retrospective, anonymized analysis of charts of patients who received at least one 0.7 mg dexamethasone (Ozurdex®) injection to treat macular oedema due to branch retinal vein occlusion or central retinal vein occlusion. The data were collected during the initial, follow-up and final visits at the following time-points: 1.: days 2–63, 2.: days 64–126, 3.: 127–210, 4.: 211–294, 5.: ≥295 days and at special time-point: days 46–87.
Results:Data for 43 patients were available for analysis. In 63% of patients following dexamethasone intravitreal implant we observed an improvement of at least 2 lines in best corrected visual acuity and in 53% patients – an improvement of at least 3 lines in best corrected visual acuity (corresponding to at least a 15-letter improvement). Statistical significant mean change in best corrected visual acuity after conversion to ETDRS letters, was observed at time-point 1: 18.66 ± 20.27, at time-point 2: 10 ± 19 and at special time-point: 13.96 ± 22.14 after the first injection, and at time-point 1: 29.17 ± 19.22 after second injection. Central retinal thickness was significantly reduced compared to baseline at each time-point, while the highest mean change observed at the special time-point was -355.08 ± 184.72 µm (p<0.001). During the study 29 patients experienced at least one adverse event. No serious adverse events were observed. The most common reported adverse events were increased intraocular pressure (28%), conjunctival haemorrhage (26%) and conjunctival hyperaemia (23%).
Conclusions: The results of retrospective study confirmed that dexamethasone injection in patients with macular oedema due to branch retinal vein occlusion or central retinal vein occlusion causes best corrected visual acuity improvement and central retinal thickness reduction.

Słowa kluczowe: niedrożność żyły środkowej siatkówki (CRVO), niedrożność gałązki żyły środkowej siatkówki (BRVO), doszklistkowe iniekcje dexametazonu – Ozurdex, obrzęk plamki.

Keywords: central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), intravitreal dexamethasone injections – Ozurdex, macular oedema.

powrót